AIM AIM ImmunoTech Inc

Price (delayed)

$0.3649

Market cap

$18.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$18.77M

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease ...

Highlights

AIM ImmunoTech's gross profit has surged by 64% YoY but it has decreased by 11% QoQ

AIM ImmunoTech's gross margin has increased by 33% YoY but it has decreased by 6% from the previous quarter

AIM ImmunoTech's quick ratio has plunged by 93% YoY and by 26% from the previous quarter

AIM ImmunoTech's equity has shrunk by 86% YoY and by 53% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: https://aimimmuno.com/

Peers: OPK OPTN

Key stats

What are the main financial stats of AIM

Market

Shares outstanding

51.28M

Market cap

$18.71M

Enterprise value

$18.77M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

3.69

Price to sales (P/S)

93.51

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

97.24

Earnings

Revenue

$193,000

EBIT

-$31.05M

EBITDA

-$30.58M

Free cash flow

-$22.43M

Per share

EPS

-$0.64

Free cash flow per share

-$0.45

Book value per share

$0.1

Revenue per share

TBVPS

$0.28

Balance sheet

Total assets

$16.19M

Total liabilities

$11.36M

Debt

$3.35M

Equity

$4.83M

Working capital

$1.43M

Liquidity

Debt to equity

0.69

Current ratio

1.14

Quick ratio

1.11

Net debt/EBITDA

Margins

EBITDA margin

-15,843%

Gross margin

74.1%

Net margin

-16,123.3%

Operating margin

-17,261.7%

Efficiency

Return on assets

-128.3%

Return on equity

-183.6%

Return on invested capital

-547.4%

Return on capital employed

-491.8%

Return on sales

-16,086%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

AIM stock price

How has the AIM ImmunoTech stock price performed over time

Intraday

1.36%

1 week

-1.38%

1 month

-3.97%

1 year

-36.33%

YTD

-17.05%

QTD

-1.38%

Financial performance

How have AIM ImmunoTech's revenue and profit performed over time

Revenue

$193,000

Gross profit

$143,000

Operating income

-$33.32M

Net income

-$31.12M

Gross margin

74.1%

Net margin

-16,123.3%

AIM ImmunoTech's gross profit has surged by 64% YoY but it has decreased by 11% QoQ

The net income has plunged by 61% YoY and by 7% from the previous quarter

The operating income has plunged by 58% YoY and by 4.4% from the previous quarter

AIM ImmunoTech's gross margin has increased by 33% YoY but it has decreased by 6% from the previous quarter

Growth

What is AIM ImmunoTech's growth rate over time

Valuation

What is AIM ImmunoTech stock price valuation

P/E

N/A

P/B

3.69

P/S

93.51

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

97.24

The company's EPS has shrunk by 60% YoY and by 7% QoQ

The P/B is 178% higher than the 5-year quarterly average of 1.3 and 64% higher than the last 4 quarters average of 2.2

AIM ImmunoTech's equity has shrunk by 86% YoY and by 53% QoQ

AIM's P/S is 69% below its 5-year quarterly average of 299.1 and 32% below its last 4 quarters average of 133.6

AIM ImmunoTech's revenue has increased by 24% YoY but it has decreased by 4.5% QoQ

Efficiency

How efficient is AIM ImmunoTech business performance

AIM's ROA has shrunk by 191% YoY and by 31% QoQ

The ROE has plunged by 55% from the previous quarter

The return on invested capital has declined by 41% since the previous quarter

The company's return on sales fell by 30% YoY and by 12% QoQ

Dividends

What is AIM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for AIM.

Financial health

How did AIM ImmunoTech financials performed over time

The total assets is 42% greater than the total liabilities

AIM's current ratio has dropped by 94% year-on-year and by 32% since the previous quarter

AIM ImmunoTech's quick ratio has plunged by 93% YoY and by 26% from the previous quarter

The debt is 31% smaller than the equity

AIM ImmunoTech's equity has shrunk by 86% YoY and by 53% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.